RIPK4 and melanoma: However, whether downregulation of RIPK4 can serve as a promising therapeutic strategy to overcome resistance to CisPt or DOX in mul-targeted melanoma chemotherapy requires further investigation on a broader panel of melanoma cell lines and preclinical models.